New Results for Targeted Radioligand Therapy 177Lu-NeoB Suggest Promise in Certain Breast and Prostate Cancers 10 months ago JohnIn BreakthroughsClinical Trials
European Union Issues New Horizon Europe Health Calls, Funding Phage Therapy and AI-for-Pandemic Preparedness 10 months ago JohnIn Breaking News
I-SPY2.2 Trial Adopts Smart Adaptive Design to Personalize Breast Cancer Treatment Regimens 10 months ago JohnIn Research Updates
FDA Panel Raises Concerns Over Applicability of STARGLO Trial in DLBCL Despite Positive Outcomes 10 months ago JohnIn FDA ApprovalsTop Stories
FDA Grants Full Approval to Novavax’s Nuvaxovid Vaccine with Specific Age and Risk-Conditions Restrictions 10 months ago JohnIn FDA ApprovalsFeatured Analysis
New Data Suggests Aficamten Improves Symptoms in Obstructive Hypertrophic Cardiomyopathy Across Diverse Patient Groups 10 months ago JohnIn Biopharma HighlightsBreaking NewsClinical TrialsResearch Updates
Novel Bayesian Hybrid Design Could Speed Up Multinational Trials While Preserving Rigor 10 months ago JohnIn InnovationPharma Industry Updates
New Hope for Rett Syndrome: TSHA-102 Pivotal Trial Moves into Site Activation Stage 11 months ago JohnIn Clinical TrialsInnovationStartups
Bharat Biotech’s Hillchol Oral Cholera Vaccine Clears Phase III with Strong Protection 11 months ago JohnIn Clinical TrialsResearch UpdatesVenture Capital
AbCellera Gets Green Light in Canada for First-in-Human Trial of ABCL635 to Treat Menopause Vasomotor Symptoms 11 months ago JohnIn Clinical Trials
EMA Greenlights Moleculin’s Phase IIb/III Trial of Annamycin Plus Ara-C in AML 11 months ago JohnIn Breaking News
FDA Grants Approval to Emrelis (Telisotuzumab Vedotin) for Advanced NSCLC with c-Met Overexpression 11 months ago JohnIn FDA ApprovalsResearch Updates
New Data from Votoplam (PTC518) Offers Hope for Huntingtin Reduction in Huntington’s Disease 11 months ago JohnIn Clinical Trials
Merus’ Petosemtamab Plus Keytruda Shows Strong Responses in Head and Neck Cancer Phase II Trial 11 months ago JohnIn Biopharma HighlightsResearch UpdatesTop Stories
FDA Approves First Targeted Therapy for KRAS-Mutated Low-Grade Serous Ovarian Cancer 11 months ago JohnIn Breaking NewsClinical TrialsFDA Approvals
